- Record: found
- Abstract: found
- Article: found
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease. Interleukin (IL) 13
is a type 2 cytokine that is key to the inflammation underlying AD. Tralokinumab is
a first-in-class, fully human, monoclonal antibody that specifically binds with high
affinity to IL-13, neutralizing it in AD. Immunomodulatory treatments may impair vaccine-induced
immune responses.